Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06263387
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2023-12-14
Brief Title:
Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia AML Patients Ineligible for Intensive Chemotherapy IC Treated With Venetoclax Azacitidine
Sponsor:
Organization:
French Innovative Leukemia Organisation
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
True
Target Duration:
18 Months
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
230
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Cohort |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 103726 |
Who Masked List: